SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
Introduction: Since 2008 United State (US) food drug administration mandate, several NUTMEG WHOLE ORG newer anti-diabetic drugs (ADD) have undergone a mandatory cardiovascular (CV) outcome trial (CVOT) in type diabetes (T2DM) patients with high CV risk.These includes CVOT done with dipeptidyl-peptidase-4 inhibitors, sodium-glucose co-transporter-2